Pins and needles: Pinterest tackles spread of vaccine misinformation

Medical News | August 30, 2019

Pins and needles: Pinterest tackles spread of vaccine misinformation
Pinterest, the social media web and mobile application company which collates information on a variety of sites by topic, recognizes the critical role that social media plays in spreading health misinformation, and has taken several radical steps to correct this. First, in 2018, Pinterest voluntarily stopped showing results for searches related to vaccines. Instead, the page simply said, “If you’re looking for medical advice, please contact a healthcare provider.” It asked experts how it could improve this search. As a result, the company put many leading antivaccine websites on its banned list, and blocked the URLs in toto, so that anything from that website can no longer be pinned. Hundreds of such actions have been taken, it says. The social media giant has now taken another bold step: it will show results to searches for over 200 vaccine-related search terms like “vaccine safety”, or “measles”, but all the results will come from public health organizations. These include the Centers for Disease Control (CDC), the World Health Organization (WHO), and its auxiliary, the Vaccine Safety Net.

Spotlight

Following the publication of Radford’s Q4 2017 Workforce Trends Report for life sciences companies, our team examined hiring plans and turnover rates across the world’s major economies, including Brazil, China, India, Germany, Russia, the UK and the US. The data shows some surprising declines in aggressive hiring plans in several key markets.

Spotlight

Following the publication of Radford’s Q4 2017 Workforce Trends Report for life sciences companies, our team examined hiring plans and turnover rates across the world’s major economies, including Brazil, China, India, Germany, Russia, the UK and the US. The data shows some surprising declines in aggressive hiring plans in several key markets.

Related News

Ionis and Genuity Science announce agreement designed to rapidly translate genomic insights into therapeutics

Prnewswire | October 01, 2020

Genuity Science, a genomics and data insights organization and Ionis Pharmaceuticals (NASDAQ: IONS), the leader in antisense therapeutics, today announced a broad, multi-year collaboration aimed at accelerating the discovery and development of innovative therapeutics across a range of up to 20 diseases. The collaboration is expected to play an important role in allowing Ionis to continue delivering transformational medicines to patients for many years to come. Genuity Science's approach combines high-quality, whole-genome sequence and deep phenotype data resulting in better definition of the underlying disease mechanisms. This approach, when coupled with Ionis' proprietary antisense technology, has the potential to significantly expedite the drug development process through a more direct translation of targets into therapeutics.

Read More

Alliance for Regenerative Medicine Published its Response to EU Pharmaceutical Roadmap

Alliance for Regenerative Medicine | July 07, 2020

The Alliance for Regenerative Medicine (ARM), the leading international advocacy organisation dedicated to realising the promise of regenerative medicines and advanced therapies, today published its response to the EU Pharmaceutical Strategy Roadmap which is designed to improve and accelerate patients’ access to safe and affordable medicines and to support innovation in the EU pharmaceutical industry. The full response can be found on the European Commission website. While ARM welcomes the Roadmap’s recognition of the wider industry’s contribution to the EU economy and its focus on ensuring patients’ access to safe, state-of-the-art therapies, ARM wants to ensure a continued pathway for the EU to benefit from innovative and life-changing advanced therapy medicinal products (ATMPs).

Read More

RESEARCH

UConn startup DIANT bags license for continuous nanoparticle manufacturing tech

UConn | November 20, 2020

Consistent assembling has just begun to override customary group handling in the domain of tablet creation. The following region due for an assembling update? Nanoparticle drug conveyance frameworks, one startup thinks—and it's currently prepared to pitch its foundation to drugmakers. The University of Connecticut as of late authorized its ceaseless nanoparticle fabricating innovation to DIANT Pharma, a startup helped to establish by the stage's designers Antonio Costa, Ph.D., and Diane Burgess, Ph.D. The high-throughput framework can possibly spare tidy up room space, bring down the quantity of preparing steps and diminish the quantity of bunches created every year. Since the stage is persistent, it should empower makers to hop in the event that anything turns out badly, redirecting or eliminating just a little bit of the item instead of rejecting a whole group, Costa, CEO at DIANT and partner research teacher at UConn, said in a meeting.

Read More